Literature DB >> 19145446

[Systemic lupus erythematosus. Target criteria for treatment].

T Alexander1, R Biesen, A Jacobi, B Hoyer, A Bruns, F Hiepe.   

Abstract

Systemic lupus erythematosus (SLE) is a chronic systemic intermittent autoimmune disease, which can affect nearly all organ systems. The disease is characterized by the detection of more than 100 different auto-antibodies. For the clinical practice as well as in controlled clinical studies it is absolutely necessary to define target criteria which allow the evaluation of the effectiveness of therapy. Many instruments are available for measuring the activity of the disease, the quality of life, the extent of irreversible damage and the individual manifestation in organs. There are also now various biomarkers to characterize the pathophysiologic aspects, clinical activity, therapeutic effectiveness and prognosis.

Entities:  

Mesh:

Year:  2009        PMID: 19145446     DOI: 10.1007/s00393-008-0359-5

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  32 in total

1.  Assessing disease activity in SLE patients during pregnancy.

Authors:  J P Buyon; K C Kalunian; R Ramsey-Goldman; M A Petri; M D Lockshin; G Ruiz-Irastorza; M Khamashta
Journal:  Lupus       Date:  1999       Impact factor: 2.911

2.  BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus.

Authors:  D A Isenberg; A Rahman; E Allen; V Farewell; M Akil; I N Bruce; D D'Cruz; B Griffiths; M Khamashta; P Maddison; N McHugh; M Snaith; L S Teh; C S Yee; A Zoma; C Gordon
Journal:  Rheumatology (Oxford)       Date:  2005-04-06       Impact factor: 7.580

3.  The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus.

Authors:  M Mosca; W Bencivelli; C Vitali; P Carrai; R Neri; S Bombardieri
Journal:  Lupus       Date:  2000       Impact factor: 2.911

4.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

5.  Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.

Authors:  Michelle Petri; William Stohl; Winn Chatham; W Joseph McCune; Marc Chevrier; Jeff Ryel; Virginia Recta; John Zhong; William Freimuth
Journal:  Arthritis Rheum       Date:  2008-08

6.  Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus.

Authors:  Robert Biesen; Cemal Demir; Fidan Barkhudarova; Joachim R Grün; Marta Steinbrich-Zöllner; Marina Backhaus; Thomas Häupl; Martin Rudwaleit; Gabriela Riemekasten; Andreas Radbruch; Falk Hiepe; Gerd-Rüdiger Burmester; Andreas Grützkau
Journal:  Arthritis Rheum       Date:  2008-04

7.  European consensus statement on the terminology used in the management of lupus glomerulonephritis.

Authors:  C Gordon; D Jayne; C Pusey; D Adu; Z Amoura; M Aringer; J Ballerin; R Cervera; J Calvo-Alén; C Chizzolini; Jm Dayer; A Doria; F Ferrario; J Floege; L Guillevin; M Haubitz; F Hiepe; F Houssiau; P Lesavre; L Lightstone; Pl Meroni; O Meyer; B Moulin; K O'Reilly; M Praga; H Schulze-Koops; Ra Sinico; Kgc Smith; A Tincani; C Vasconcelos; G Hughes
Journal:  Lupus       Date:  2009-03       Impact factor: 2.911

8.  Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95.

Authors:  Annett M Jacobi; Karin Reiter; Meggan Mackay; Cynthia Aranow; Falk Hiepe; Andreas Radbruch; Arne Hansen; Gerd-R Burmester; Betty Diamond; Peter E Lipsky; Thomas Dörner
Journal:  Arthritis Rheum       Date:  2008-06

9.  EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.

Authors:  G Bertsias; J P A Ioannidis; J Boletis; S Bombardieri; R Cervera; C Dostal; J Font; I M Gilboe; F Houssiau; T Huizinga; D Isenberg; C G M Kallenberg; M Khamashta; J C Piette; M Schneider; J Smolen; G Sturfelt; A Tincani; R van Vollenhoven; C Gordon; D T Boumpas
Journal:  Ann Rheum Dis       Date:  2007-05-15       Impact factor: 19.103

10.  Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus.

Authors:  Jason W Bauer; Emily C Baechler; Michelle Petri; Franak M Batliwalla; Dianna Crawford; Ward A Ortmann; Karl J Espe; Wentian Li; Dhavalkumar D Patel; Peter K Gregersen; Timothy W Behrens
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

View more
  2 in total

Review 1.  [Immunoablation followed by autologous stem cell transplantation in lupus: a clinical update].

Authors:  T Alexander; R Arnold; F Hiepe
Journal:  Z Rheumatol       Date:  2009-05       Impact factor: 1.372

2.  Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation.

Authors:  J A Snowden; R Saccardi; M Allez; S Ardizzone; R Arnold; R Cervera; C Denton; C Hawkey; M Labopin; G Mancardi; R Martin; J J Moore; J Passweg; C Peters; M Rabusin; M Rovira; J M van Laar; D Farge
Journal:  Bone Marrow Transplant       Date:  2011-10-17       Impact factor: 5.483

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.